Inhibitors like I-BET726 and JQ1, which target bromodomain 4 (a key factor in MYC transcription), have shown promise in blocking MYC transcription and increasing cancer cell immunogenicity by suppressing PD-L1 expression (35, 36). This evidence concerns the gene MYC and cancer.